Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study
American Journal of Cardiovascular Drugs,  Clinical Article

Majewski S et al. – This study demonstrated that selective heart rate (HR) reduction with ivabradine is effective in patients with asthma and chronic obstructive pulmonary disease (COPD), with no alteration in respiratory function or symptoms over the duration of the study. Ivabradine offers an interesting alternative, as an HR–lowering agent, in patients with respiratory disease and contraindications to β–blockers.

Methods
  • This was a randomized, single–center, double–blind, placebo–controlled, crossover trial.
  • Enrolment began in May 2009, and the last patient completed the study in January 2011.
  • The study was conducted in an ambulatory setting.
  • A total of 40 patients completed the study (20 asthmatic patients and 20 COPD patients).
  • Inclusion criteria were: documented diagnosis of asthma or COPD according to international guidelines, age 18–75 years, and mean HR on Holter ECG recording of ≥60beats/min.
  • Exclusion criteria included disease exacerbation in a previous month or inability to understand instructions on the study procedures.
  • All patients received ivabradine 7.5mg twice daily for 5 days and placebo twice daily for 5 days in a crossover manner, in one of the two arms of the study, with at least 2 days of washout between treatments.
  • The main outcome measures included the difference in HR between ivabradine and placebo treatment and change in HR in comparison with baseline.
  • Other evaluated outcomes were differences in the peak expiratory flow rate (PEFR), the daily symptom score, rescue medication consumption, and AEs.

Results
  • Ivabradine produced significantly lower mean HR than placebo in both groups of patients: asthma 67.4±8.38 versus 82.85±11.19beats/min (p<0.001) and COPD 69.75±8.9 versus 81.05±9.75beats/min (p<0.001).
  • Similar results were observed for the minimal HR as well as for the maximal noted HR.
  • In comparision with baseline, ivabradine significantly reduced HR in both groups of studied patients (all p<0.05), whereas placebo did not have such an effect.
  • No significant difference, in either the asthma or the COPD group, was found between ivabradine and placebo in morning and evening peak expiratory flow rate, peak expiratory flow diurnal variability, daily symptom scores, and rescue medication usage (all p>0.05).
  • Both treatments were well tolerated.
  • The incidence of AEs was low and generally similar in both periods of treatment, except for visual symptoms during treatment with ivabradine, which was reported by 5% of the patients.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 One injection stops diabetes in its tracks Salk Institute News, July 18, 2014

2 FDA approves Afrezza to treat diabetes Full Text FDA Press Announcements, June 30, 2014    Free full text

3 Antibiotic developed 50 years ago may be the key to fighting 'superbugs' University at Buffalo Health and Medicine News, June 19, 2014

4 Levomilnacipran: A new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder Annals of Pharmacotherapy, July 25, 2014    Review Article    Clinical Article

5 New research indicates statin drugs must be taken properly Michigan State University Health News, July 22, 2014

6 Duke team brings life-saving function to ketchup packets Duke University Health & Medicine News, July 3, 2014

7 European Commission approves Bristol-Myers Squibb’s Daklinza (daclatasvir) across multiple genotypes for the treatment of chronic hepatitis C infection Full Text Bristol Myers-Squibb, August 28, 2014    Free full text

8 “Worm pill” could ease autoimmune disease symptoms Monash University News, August 11, 2014

9 Honey as an effective antimicrobial treatment for chronic wounds Full Text Chronic Wound Care Management and Research, August 21, 2014    Free full text    Review Article

10 FDA approves new type of sleep drug, Belsomra Full Text FDA Press Announcements, August 14, 2014    Free full text

11 Is the standard dose of amoxicillin-clavulanic acid sufficient? Full Text BMC Pharmacology & Toxicology, August 8, 2014    Free full text    Clinical Article

12 Acetaminophen plus ibuprofen versus opioids for treatment of post-tonsillectomy pain in children International Journal of Pediatric Otorhinolaryngology , August 18, 2014    Clinical Article

13 Update on recommendations for use of herpes zoster vaccine Full Text Morbidity and Mortality Weekly Report, August 22, 2014    Free full text

14 Comparison of new-onset gout in adults prescribed chlorthalidone vs hydrochlorothiazide for hypertension The Journal of Clinical Hypertension, September 26, 2014    Clinical Article

15 FDA approves Jardiance to treat type 2 diabetes Full Text FDA Press Announcements, August 4, 2014    Free full text

16 Intracranial hemorrhage risk with the new oral anticoagulants: A systematic review and meta-analysis Journal of Neurology, September 2, 2014    Evidence Based Medicine    Review Article

17 Beta-blockers in heart failure with preserved ejection fraction: A meta-analysis Heart Failure Reviews, July 28, 2014    Evidence Based Medicine    Review Article    Clinical Article

18 FDA approves Striverdi Respimat to treat chronic obstructive pulmonary disease Full Text FDA Press Announcements, August 1, 2014    Free full text

19 Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT Journal of the American Society of Hypertension, September 15, 2014    Clinical Article

20 Digoxin tied to increased risk of death in patients with atrial fibrillation Stanford School of Medicine News, August 12, 2014

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close